A study designed to treat patients with back pain associated with degenerative lumbar disc disease.
This study is designed to evaluate the safety and effectiveness of the ReGelTec HYDRAFIL System in subjects with axial low back pain (LBP) due to degenerative disc disease (DDD) who continue to have severe back pain and dysfunction after at least six (6) months of conservative care. The primary objective of this study is to evaluate the safety and efficacy the HYDRAFIL System.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
35
The HYDRAFIL System contains the following items: the Delivery System and the Pressure Gauge. The HYDRAFIL implant is contained within a pre-filled syringe that is inserted into the delivery system housing during the manufacturing process. The implant is heated within the delivery system prior to use to ensure a flowable implant that can be injected through a standard coaxial needle.
Beam Interventional & Diagnostic Imaging
Calgary, Alberta, Canada
Success
Successful implantation of the ReGelTec HYDRAFIL System implant in a lumbar disc nucleus
Time frame: post-treatment
Back pain as measured by NRS
Decrease in Numeric Rating Scale (NRS) Score - Back Pain
Time frame: 3, 6, 12 and 24 months
Function as measured by ODI
Maintenance of, or further improvement in the Oswestry Disability Index (ODI) Score
Time frame: 3, 6, 12 and 24 months
Safety of the ReGelTec Implant by demonstrating durability over the long term and no unanticipated safety concerns that arise
Freedom from Device or Operative Related Serious Adverse Events (SAEs)
Time frame: 3, 6, 12 and 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.